Holen Sie sich die Stockscreener-App
203.55
0.16%
-0.32
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
Farther Finance Advisors LLC Increases Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
Price Over Earnings Overview: AbbVie - Benzinga
AbbVie (NYSE:ABBV) Shares Up 0.1% Following Analyst Upgrade - MarketBeat
Expert Insights: The Promise of Genetic Medicine and AbbVie’s Role in Research - AbbVie
AbbVie and Gedeon Richter partner on neuropsychiatric conditions - The Pharma Letter
AbbVie raises profit forecast as CEO cites business "momentum" - MSN
AbbVie Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
AbbVie Inc. (NYSE:ABBV) Shares Bought by Principal Securities Inc. - MarketBeat
William Blair Estimates AbbVie's FY2024 Earnings (NYSE:ABBV) - MarketBeat
AbbVie and EvolveImmune Therapeutics sign oncology collaboration - Pharmaceutical Technology
Rx Rundown: AbbVie, Biogen, GSK and more - MM+M Online
AbbVie Stock Rises After Earnings Beat, Dividend Hike - MSN
AbbVie and EvolveImmune partner to develop advanced cancer therapies - World Pharmaceutical Frontiers
AbbVie’s Deal for Alzheimer’s Antibody Raises Curtain for Roche News on Wednesday - Barron's
UChicago gets $75M from AbbVie Foundation for new cancer center - The Business Journals
AbbVie (NYSE:ABBV) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
University of Chicago Medicine gets $75 million gift from AbbVie Foundation for new cancer center - CBS News
AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter
Evolveimmune snags another investor, inks $1.4B Abbvie deal - BioWorld Online
AbbVie (NYSE:ABBV) Trading 1.5% Higher After Better-Than-Expected Earnings - MarketBeat
AbbVie partners with EvolveImmune for cancer therapy - Investing.com
AbbVie's multibillion-dollar collaboration targets new cancer therapy candidate - Crain's Chicago Business
AbbVie price target raised to $200 from $195 at UBS - TipRanks
AbbVie (NYSE:ABBV) Hits New 12-Month High on Strong Earnings - MarketBeat
AbbVie (NYSE:ABBV) Price Target Raised to $231.00 - MarketBeat
AbbVie Foundation's $75M gift will put its name on new UChicago cancer hospital - Crain's Chicago Business
BMO increases AbbVie stock target, outperform on upbeat quarterly results - Investing.com
AbbVie Inc. (NYSE:ABBV) Q3 2024 Earnings Call Transcript - Insider Monkey
AbbVie Beats Q3 Estimates as Skyrizi, Rinvoq Pick Up Slack for Humira - BioSpace
AbbVie, EvolveImmune Therapeutics Set Cancer Biotherapeutics Collaboration - MarketWatch
Earnings call: AbbVie raises outlook on strong Q3 performance, Skyrizi and Rinvoq growth - Investing.com India
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-To- License Agreement to Develop Next-Generation Cancer Biotherapeutics - Marketscreener.com
AbbVie Inc. (NYSE:ABBV) Shares Bought by JFS Wealth Advisors LLC - MarketBeat
AbbVie (NYSE:ABBV) Updates Q4 2024 Earnings Guidance - MarketBeat
5 Dividend Stocks to Double Up on Right Now -- Plus Some Dividend ETFs - The Motley Fool
AbbVie Inc (ABBV) Q3 2024 Earnings Call Highlights: Strong Growth in Ex-Humira Platform and ... - Yahoo Finance
AbbVie reports 12% decline in Q3 2024 net income to $1.56bn - World Pharmaceutical Frontiers
AbbVie Reports Solid Q3 2024 Financial Performance - TipRanks
AbbVie: 3 Positives From The Earnings Report (NYSE:ABBV) - Seeking Alpha
AbbVie Inc. (NYSE:ABBV) Short Interest Up 8.9% in October - MarketBeat
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter Beat - MSN
Super Micro, Alphabet, AMD, Lilly, Reddit, AbbVie, Qorvo, Garmin, and More Movers - Barron's
AbbVie Earnings: Maintaining Fair Value Estimate as Firm Rapidly Pushes Through Humira Headwind - Morningstar
AbbVie Stock Jumps After Upbeat Q3 Earnings, Revised Guidance: Retail Sentiment Hits One-Year High - Barchart
Reasons behind AbbVie Q3 revenue beat? (ABBV:NYSE) - Seeking Alpha
AbbVie stock soars to all-time high of $199.96 amid robust growth By Investing.com - Investing.com South Africa
Committee Stocks on the Move: Shake Shack, Chipotle, Wingstop, Visa and AbbVie - CNBC
AbbVie (ABBV) Q3 2024 Earnings Call Transcript - Nasdaq
AbbVie stock soars to all-time high of $199.96 amid robust growth - Investing.com Canada
AbbVie Trumps Q3 Earnings & Sales Estimates, Raises '24 EPS View - Yahoo Finance
AbbVie 3rd-qtr financials beat expectations - The Pharma Letter
AbbVie (NYSE:ABBV) Stock Price Up 3.2% After Dividend Announcement - MarketBeat
AbbVie raises 2024 profit forecast on strong sales of key drugs Skyrizi, Rinvoq - Reuters
AbbVie Inc. (NYSE:ABBV) Plans Dividend Increase$1.64 Per Share - MarketBeat
Compared to Estimates, AbbVie (ABBV) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
AbbVie (NYSE:ABBV) Issues FY24 Earnings Guidance - MarketBeat
ABBV Earnings: AbbVie Reports Strong Q3 Results, Raises Outlook - TipRanks
AbbVie says ‘pleased’ with progress advancing product pipeline - TipRanks
AbbVie: Q3 Earnings Snapshot - The Washington Post
0.17%
0.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):